You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (14)

Journals (0)

1-10 of 14 results for partitioned survival cost-utility analysis

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: A Bayesian Framework for Patient-Level Partitioned Survival Cost-Utility Analysis

Open access

Research article

First published 2021-11

A Bayesian Framework for Patient-Level Partitioned Survival Cost-Utility Analysis

Andrea Gabrio

Medical Decision Making

Select article: Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer

Open access

Research article

First published 2019

Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer

Ravasio R, Tiseo M, Pradelli L [...]

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish

Select article: Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis

Open access

Research article

First published 2023

Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis

Gaofeng Zhu, Hongfu Cai, Zhiwei Zheng

Therapeutic Advances in Medical Oncology

Select article: First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis

Open access

Research article

First published 2024

First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis

Guiyuan Xiang, Yueyue Huang, Ni Zhang [...]

Clinical Medicine Insights: Oncology

Select article: Cost-effectiveness analysis of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy for advanced HER2-negative gastric or gastro-esophageal junction cancer

Open access

Research article

First published 2025

Cost-effectiveness analysis of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy for advanced HER2-negative gastric or gastro-esophageal junction cancer

Yitian Lang, Weican Cao, Yan Lin [...]

Therapeutic Advances in Gastroenterology

Select article: Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR -mutated advanced lung cancer

Open access

Research article

First published 2025

Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR -mutated advanced lung cancer

Li-Jung Elizabeth Ku, Jui-Hung Tsai, Li-Jun Chen [...]

Therapeutic Advances in Medical Oncology

Select article: Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China

Open access

Research article

First published 2025

Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China

Baolong Ding, Hongting Yao, Tiantian Tao [...]

Therapeutic Advances in Medical Oncology

Select article: Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis

Open access

Research article

First published 2026

Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis

Huijie Qi, Yuxin Huang, Wenxin Zhang [...]

Therapeutic Advances in Medical Oncology

Select article: Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective

Open access

Research article

First published 2026

Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective

Hanrui Zheng, Feng Wen, Bin Wu

Clinical Medicine Insights: Oncology

Select article: Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis

Open access

Research article

First published 2026

Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis

Jia Wang, Baolong Ding, Zhuying Jing [...]

Therapeutic Advances in Medical Oncology

1
2
10 / page

Article type

Publication date

Subjects

Access